Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19038137 | 1-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDS | January 2025 | December 2025 | Allow | 10 | 1 | 0 | No | No |
| 18985720 | DITHIENYL DISULFIRAM DERIVATIVES AS SELECTIVE ALDH1A1 INHIBITORS | December 2024 | May 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18973200 | RUXOLITINIB FOR THE TREATMENT OF PRURIGO NODULARIS | December 2024 | September 2025 | Allow | 9 | 2 | 0 | Yes | No |
| 18923566 | MrgprX2 Antagonists for the Treatment of Inflammatory Disorders | October 2024 | September 2025 | Allow | 11 | 2 | 2 | Yes | No |
| 18912939 | RUXOLITINIB FOR THE TREATMENT OF PRURIGO NODULARIS | October 2024 | August 2025 | Abandon | 10 | 1 | 0 | No | No |
| 18884941 | METHODS OF REDUCING ITCH USING TOPICAL ROFLUMILAST COMPOSITIONS | September 2024 | March 2026 | Abandon | 18 | 3 | 0 | Yes | No |
| 18812527 | MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOF | August 2024 | March 2025 | Allow | 7 | 1 | 1 | Yes | No |
| 18759222 | TOPICAL FORMULATIONS FOR INFECTIONS | June 2024 | November 2025 | Allow | 17 | 2 | 1 | Yes | No |
| 18661306 | METHOD OF TREATING SEIZURES AND EPILEPSY USING LIQUID PHARMACEUTICAL COMPOSITION FOR ORAL DOSAGE OF VIGABATRIN | May 2024 | September 2025 | Allow | 17 | 1 | 0 | No | No |
| 18658848 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | May 2024 | September 2025 | Allow | 16 | 1 | 1 | Yes | No |
| 18652993 | RAMIPRIL SOLUTION FOR ORAL DOSAGE | May 2024 | May 2025 | Allow | 12 | 2 | 1 | Yes | No |
| 18646365 | COMPOSITION COMPRISING LIPOIC ACID AND VITAMIN D FOR THE PREVENTION AND THE TREATMENT OF NEURODEGENERATIVE DISEASES AND PERIPHERAL NEUROPATHIES | April 2024 | December 2025 | Abandon | 19 | 1 | 0 | No | No |
| 18638340 | OTIC FORMULATIONS, METHODS AND DEVICES | April 2024 | August 2025 | Allow | 16 | 1 | 0 | No | No |
| 18602482 | PAIN TREATING COMPOUNDS AND USES THEREOF | March 2024 | January 2026 | Abandon | 23 | 1 | 1 | No | No |
| 18591969 | CRYSTALLINE SALTS OF PSILOCIN | February 2024 | March 2025 | Allow | 12 | 0 | 1 | Yes | No |
| 18591925 | CRYSTALLINE SALTS OF PSILOCIN | February 2024 | March 2025 | Allow | 12 | 0 | 1 | Yes | No |
| 18685899 | ABIRATERONE PRECURSOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | February 2024 | June 2025 | Allow | 16 | 2 | 1 | Yes | No |
| 18407729 | FGFR INHIBITOR FOR USE IN THE TREATMENT OF HYPOPHOSPHATEMIC DISORDERS | January 2024 | July 2025 | Abandon | 19 | 1 | 0 | No | No |
| 18544952 | NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE | December 2023 | August 2025 | Allow | 20 | 1 | 0 | No | No |
| 18529689 | TEAD INHIBITORS AND METHODS OF USES THEREOF | December 2023 | April 2024 | Allow | 5 | 0 | 1 | Yes | No |
| 18506138 | ARTIFICIALLY SYNTHESIZED SPHINGOSINE DERIVATIVE LIPOID MONOMER AND USE OF SAME FOR DELIVERING NUCLEIC ACID | November 2023 | January 2026 | Allow | 26 | 2 | 1 | Yes | No |
| 18278628 | PHARMACEUTICAL COMPOSITION OF FORSKOLIN-ISOFORSKOLIN AND PENTACYCLIC TRITERPENOID COMPOUND, AND APPLICATION THEREOF | October 2023 | June 2025 | Abandon | 22 | 2 | 1 | No | No |
| 18486668 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | October 2023 | September 2025 | Allow | 24 | 1 | 1 | Yes | No |
| 18480898 | RUXOLITINIB FOR THE TREATMENT OF PRURIGO NODULARIS | October 2023 | March 2025 | Abandon | 17 | 1 | 0 | No | No |
| 18370069 | CLEAVABLE CONJUGATES OF CATECHOL COMPOUNDS AND WATER-SOLUBLE POLYMERS AND METHODS OF TREATMENT USING THE SAME | September 2023 | February 2026 | Allow | 29 | 2 | 1 | Yes | No |
| 18279031 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PLASMODIUM FALCIPARUM MALARIA | August 2023 | September 2025 | Allow | 25 | 1 | 1 | Yes | No |
| 18236839 | Contraceptive Compositions and Methods for Improved Efficacy and Modulation of Side Effects | August 2023 | July 2025 | Abandon | 23 | 1 | 1 | No | No |
| 18344336 | RIBOCIL C ANTIBIOTICS EFFECTIVE FOR GRAM-NEGATIVE PATHOGENS | June 2023 | August 2024 | Allow | 14 | 0 | 1 | Yes | No |
| 18344555 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | June 2023 | December 2024 | Abandon | 17 | 0 | 1 | No | No |
| 18340006 | METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTION | June 2023 | November 2023 | Allow | 4 | 1 | 0 | No | No |
| 18338717 | USE OF FATTY ACID OXIDATION INHIBITORS AS ANTIMICROBIALS | June 2023 | December 2025 | Allow | 30 | 3 | 0 | No | No |
| 18337623 | PRODUCTION METHOD FOR RADIOLABELED ARYL COMPOUND | June 2023 | June 2025 | Allow | 23 | 2 | 1 | Yes | No |
| 18267202 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | June 2023 | March 2026 | Allow | 33 | 0 | 0 | Yes | No |
| 18208025 | METHOD FOR DIFFERENTIALLY DIAGNOSING ACTH-DEPENDENT CUSHING'S SYNDROME | June 2023 | October 2024 | Abandon | 16 | 0 | 1 | No | No |
| 18202681 | SELECTIVE DETECTION OF BED BUGS | May 2023 | March 2025 | Allow | 21 | 1 | 1 | Yes | No |
| 18311126 | STABLE LIQUID VIGABATRIN PHARMACEUTICAL COMPOSITION FOR ORAL DOSAGE | May 2023 | May 2024 | Allow | 12 | 0 | 1 | Yes | No |
| 18304270 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | April 2023 | February 2024 | Allow | 10 | 1 | 1 | Yes | No |
| 18301099 | METHOD AND COMPOSITION FOR TREATING CNS DISORDERS | April 2023 | September 2025 | Allow | 30 | 2 | 1 | Yes | No |
| 18300312 | COMBINATION THERAPY FOR PI3K-ASSOCIATED DISEASE OR DISORDER | April 2023 | November 2024 | Abandon | 19 | 0 | 1 | No | No |
| 18129267 | Methods for the Prevention and Treatment of Hearing Loss using Oseltamivir | March 2023 | April 2024 | Allow | 13 | 1 | 1 | Yes | No |
| 18128075 | COMPOSITIONS AND METHODS FOR TREATING RENAL INJURY | March 2023 | February 2025 | Abandon | 23 | 1 | 1 | No | No |
| 18184618 | DIETARY CHOLINE SUPPLEMENTATION TO REDUCE TUMOR VOLUME AND ENHANCE COGNITIVE RESPONSE DURING CANCER TREATMENT | March 2023 | July 2024 | Abandon | 17 | 1 | 1 | No | No |
| 18184513 | SYSTEMIC ISOXAZOLINE PARASITICIDES FOR VECTOR-BORNE AND VIRAL DISEASE TREATMENT OR PROPHYLAXIS | March 2023 | September 2025 | Abandon | 30 | 4 | 0 | Yes | Yes |
| 18120189 | METHODS FOR IDENTIFYING PRE-DISPOSITION TO COGNITIVE DECLINE AND AGENTS FOR REDUCING OR PREVENTING COGNITIVE DECLINE, OR IMPROVING COGNITIVE ABILITY | March 2023 | November 2025 | Allow | 32 | 4 | 1 | Yes | No |
| 18160897 | COMPOSITIONS AND METHODS FOR INHIBITING CARP-1 BINDING TO NEMO | January 2023 | March 2024 | Abandon | 14 | 0 | 1 | No | No |
| 18017471 | APPLICATION OF ARTEMISININ COMPOUND IN TREATMENT OF CORONAVIRUS INFECTION | January 2023 | March 2026 | Abandon | 38 | 1 | 0 | No | No |
| 18006125 | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO STRUCTURAL ABNORMALITIES OF THE BRAIN | January 2023 | March 2026 | Abandon | 38 | 1 | 0 | No | No |
| 18153954 | PROPHYLAXIS AND REVERSAL OF STIMULANT AND OPIOID/OPIATE OVERDOSE AND/OR TOXIC EXPOSURE | January 2023 | January 2024 | Abandon | 12 | 0 | 1 | No | No |
| 18146698 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | December 2022 | November 2024 | Allow | 22 | 1 | 1 | Yes | No |
| 18146393 | COMPOSITIONS COMPRISING CAROTENOIDS, METHODS AND APPLICATION THEREOF | December 2022 | February 2025 | Abandon | 26 | 2 | 1 | Yes | No |
| 18063695 | USE OF TETRANDRINE IN COMBINATION WITH ALL-TRANS RETINOIC ACID IN PREPARATION OF MEDICAMENT FOR TREATING PNEUMOCONIOSIS | December 2022 | January 2025 | Abandon | 25 | 2 | 1 | No | No |
| 18075163 | DISULFIRAM DERIVATIVES AS ALDH1A1 AND MAGL INHIBITORS | December 2022 | September 2024 | Allow | 22 | 1 | 0 | Yes | No |
| 17992254 | FENFLURAMINE FOR TREATMENT OF CONDITIONS ASSOCIATED WITH SPREADING DEPOLARIZATION | November 2022 | January 2025 | Abandon | 36 | 2 | 1 | No | No |
| 17985740 | TREATING LIVER DISORDERS WITH AN SSAO INHIBITOR | November 2022 | February 2025 | Abandon | 28 | 2 | 1 | No | No |
| 18053648 | COMPOSITIONS AND METHODS FOR IMPROVING COGNITIVE FUNCTION | November 2022 | September 2025 | Abandon | 34 | 4 | 0 | Yes | Yes |
| 17970933 | TOPICAL TRANEXAMIC ACID COMPOSITIONS AND METHODS OF USE THEREOF | October 2022 | March 2023 | Allow | 5 | 1 | 0 | Yes | No |
| 17965569 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | October 2022 | November 2023 | Allow | 13 | 1 | 1 | Yes | No |
| 17915123 | USE OF A THIENOPYRIDONE DERIVATIVE IN THE TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) | September 2022 | March 2025 | Allow | 29 | 3 | 1 | Yes | No |
| 17954319 | COMPOSITION FOR MODULATING HYDROGEN ION PHYSIOLOGY RELATED TO BRAIN HEALTH COMPONENT | September 2022 | August 2024 | Abandon | 23 | 2 | 1 | Yes | No |
| 17934625 | PYRIDAZINES | September 2022 | December 2023 | Allow | 14 | 2 | 1 | Yes | No |
| 17948180 | PSILOCYBIN DERIVED COMPOSITIONS AND METHODS USING SAME | September 2022 | August 2025 | Allow | 35 | 3 | 1 | Yes | No |
| 17906045 | JAK KINASE INHIBITOR AND PREPARATION AND APPLICATION THEREOF | September 2022 | January 2026 | Abandon | 40 | 1 | 0 | No | No |
| 17908858 | CRYSTAL FORMS OF METHYL(2R*,4R*)-4-[[(5S)-3-(3,5-DIFLUOROPHENYL)-5-VINYL-4H-ISOXAZOLE-5-CARBONYL]AMINO]TETRAHYDROFURAN-2-CARBOXYLATE AND THEIR HERBICIDAL SYNERGISTIC EFFECTS | September 2022 | February 2026 | Allow | 42 | 2 | 0 | Yes | No |
| 17901775 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | September 2022 | February 2024 | Allow | 18 | 1 | 0 | No | No |
| 17895667 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | August 2022 | December 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17818846 | CRYSTALLINE FORM OF TOLEBRUTINIB | August 2022 | March 2023 | Allow | 8 | 1 | 1 | Yes | No |
| 17807083 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | June 2022 | February 2024 | Allow | 20 | 1 | 1 | No | No |
| 17782780 | PHARMACEUTICAL COMPOSITION, COMPLEMENTARY KIT AND APPLICATION THEREOF | June 2022 | December 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17751998 | CRYSTALLINE SALTS OF PSILOCIN | May 2022 | December 2023 | Allow | 18 | 1 | 1 | Yes | No |
| 17752526 | USES OF A SOMATOSTATIN MODULATOR FOR THE TREATMENT OF DISEASE | May 2022 | October 2024 | Abandon | 29 | 2 | 0 | No | No |
| 17749082 | PROPHYLAXIS AND REVERSAL OF STIMULANT AND OPIOID/OPIATE OVERDOSE AND/OR TOXIC EXPOSURE | May 2022 | August 2023 | Abandon | 15 | 2 | 0 | No | No |
| 17736773 | IMPROVING THE QUALITY OF HUMAN OOCYTES | May 2022 | August 2024 | Abandon | 27 | 2 | 1 | Yes | No |
| 17734601 | LSD AND PSILOCYBIN DOSE EQUIVALENCE DETERMINATION | May 2022 | April 2025 | Abandon | 36 | 3 | 1 | No | No |
| 17721789 | COMPOSITIONS AND METHODS FOR PROMOTING SLEEP | April 2022 | April 2024 | Abandon | 24 | 1 | 1 | No | No |
| 17697039 | COMPOSITIONS AND METHODS FOR TREATMENT OF FRAGILE X SYNDROME | March 2022 | September 2025 | Allow | 42 | 1 | 1 | No | No |
| 17689607 | CANNABINOIDS IN THE TREATMENT OF EPILEPSY | March 2022 | October 2025 | Abandon | 43 | 1 | 0 | Yes | No |
| 17678990 | TREATMENT OF A RESPIRATORY CORONAVIRUS INFECTION WITH NITROXIDES | February 2022 | May 2023 | Abandon | 15 | 2 | 0 | Yes | No |
| 17628848 | COMBINATION TREATMENT OF LIVER DISEASES USING FXR AGONISTS | January 2022 | August 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17624792 | METHOD FOR PREVENTING HAIR LOSS | January 2022 | September 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17623477 | CAPACITATIVE CALCIUM ENTRY INHIBITORS | December 2021 | June 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17618345 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | December 2021 | December 2025 | Abandon | 48 | 1 | 1 | No | No |
| 17545864 | COMPOSITIONS AND METHODS FOR REDUCING CANCER STEM CELL GROWTH | December 2021 | March 2024 | Allow | 27 | 4 | 0 | Yes | No |
| 17541035 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | December 2021 | May 2022 | Allow | 6 | 1 | 1 | No | No |
| 17540826 | DISULFIRAM DERIVATIVES AS ALDH1A1 AND MAGL INHIBITORS | December 2021 | May 2023 | Allow | 17 | 3 | 1 | Yes | Yes |
| 17595772 | DIAZEPINONE DERIVATIVES AS CAPSID ASSEMBLY MODULATORS | November 2021 | May 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17612957 | OXATHIAZIN_DIOXIDE FOR TREATING, PREVENTING, INHIBITING OR REDUCING CYTOKINE RELEASE | November 2021 | November 2025 | Allow | 48 | 2 | 1 | Yes | No |
| 17610531 | MATRIX COMPOSITION COMPRISING (S)-5-BENZYL-N-(5-METHYL-4-OXO-2,3,4,5-TETRAHYDROBENZO[B][1,4]OXAZEPIN-3-YL)-4H-1,2,4-TRIAZOLE-3-CARBOXAMIDE | November 2021 | October 2025 | Abandon | 47 | 0 | 1 | No | No |
| 17607632 | METHODS OF TREATING PRURITUS | October 2021 | June 2025 | Abandon | 43 | 3 | 1 | Yes | No |
| 17515372 | METHOD FOR PRODUCING ORAL DISINTEGRATING FILM COMPRISING POORLY SOLUBLE DRUG | October 2021 | April 2024 | Abandon | 29 | 4 | 1 | Yes | No |
| 17607464 | SALT OF DIAMINOPYRIMIDINE COMPOUNDS, AND SOLID FORM THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | October 2021 | July 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17507970 | COMPOSITIONS OF AUTOPHAGY MODULATING AGENTS AND USES THEREOF | October 2021 | August 2025 | Allow | 45 | 3 | 1 | Yes | No |
| 17503126 | LIQUID PHARMACEUTICAL COMPOSITIONS | October 2021 | January 2024 | Abandon | 27 | 1 | 0 | No | No |
| 17502559 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | October 2021 | September 2024 | Allow | 35 | 3 | 1 | Yes | No |
| 17604371 | COMBINATION THERAPY | October 2021 | December 2024 | Abandon | 38 | 2 | 1 | No | No |
| 17501799 | MONO-(ACID) SALTS OF 6-AMINOISOQUINOLINES AND USES THEREOF | October 2021 | December 2025 | Abandon | 50 | 2 | 1 | No | No |
| 17594144 | SYSTEMIC ISOXAZOLINE PARASITICIDES FOR VECTOR-BORNE AND VIRAL DISEASE TREATMENT OR PROPHYLAXIS | October 2021 | October 2025 | Abandon | 48 | 4 | 0 | No | Yes |
| 17488568 | 2-BENZOYLAMINOBENZAMIDE DERIVATIVES AS BCL-3 INHIBITORS | September 2021 | December 2024 | Abandon | 38 | 1 | 1 | No | No |
| 17440879 | NOVEL AZAINDOLE DERIVATIVE | September 2021 | April 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17439611 | PKM2 MODULATORS AND METHODS FOR THEIR USE | September 2021 | April 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17472647 | Method For Treating COVID-19 and Related Viral Infections | September 2021 | December 2023 | Abandon | 27 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WELLS, LAUREN QUINLAN.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner WELLS, LAUREN QUINLAN works in Art Unit 1622 and has examined 169 patent applications in our dataset. With an allowance rate of 34.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 40 months.
Examiner WELLS, LAUREN QUINLAN's allowance rate of 34.9% places them in the 6% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by WELLS, LAUREN QUINLAN receive 2.12 office actions before reaching final disposition. This places the examiner in the 57% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by WELLS, LAUREN QUINLAN is 40 months. This places the examiner in the 22% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +60.2% benefit to allowance rate for applications examined by WELLS, LAUREN QUINLAN. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 23.4% of applications are subsequently allowed. This success rate is in the 32% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 19.6% of cases where such amendments are filed. This entry rate is in the 23% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 50.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 78.9% are granted (fully or in part). This grant rate is in the 83% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 6.8% of allowed cases (in the 84% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.